Signal Pharmaceuticals, LLC
32 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
18
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for Methods of synthesis and purification of heteroaryl compounds (US 9,079,900) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy (US 10,391,092) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 2 fees due Mar 3 to 22, 2027 · next Mar 3
- 2 fees due Apr 13, 2027
- 1 fee due May 24, 2027The maintenance fee for Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (US 9,193,692) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 3 fees due Jun 1 to 30, 2027 · next Jun 1
- 2 fees due Sep 3 to 17, 2027 · next Sep 3
- 1 fee due Nov 12, 2027The maintenance fee for Substituted Aminopurine Compounds, Compositions Thereof, and Methods of Treatment Therewith (US 10,646,493) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,440,661 | Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,101,588 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith In force · From the USPTO record | In force | From the USPTO record | |
| US 8,372,976 | Methods of treatment comprising the administration of heteroaryl compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,383,634 | Methods of treatment using heteroaryl compounds and compositions thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 7,981,893 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith In force · From the USPTO record | In force | From the USPTO record | |
| US 7,968,556 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith In force · From the USPTO record | In force | From the USPTO record | |
| US 8,110,578 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway In force · From the USPTO record | In force | From the USPTO record | |
| US 8,492,381 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway In force · From the USPTO record | In force | From the USPTO record | |
| US 8,507,492 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway In force · From the USPTO record | In force | From the USPTO record | |
| US 8,907,087 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 91: 32 patents in force now held by others · 49 lapsed for an unpaid fee · 23 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 34 no status recorded